Market Overview

Leerink: Treasury Notice Lowers Pfizer-Allergan Deal Chances, Ownership Test Changes A 'Surprise'

Share:
Leerink: Treasury Notice Lowers Pfizer-Allergan Deal Chances, Ownership Test Changes A 'Surprise'
Related PFE
Ford Earnings Preview: After Last Week's Wall Street Presentation, Not Much New Expected
Biotech M&A Off To A Strong Start In 2018: More Deals To Follow?
Is Zejula A Flawed PARP Inhibitor? (Seeking Alpha)
Related AGN
Teva's Asthma Therapy Reslizumab Fails In Late-Stage Studies
Mike Khouw Sees Unusual Options Activity In Allergan
NYC sues Big Pharma over opioid epidemic (Seeking Alpha)

The U.S. Treasury’s latest move reduced the benefits of a deal between Pfizer Inc. (NYSE: PFE) and Allergan plc Ordinary Shares (NYSE: AGN), while limiting the number of corporate tax inversions.

Leerink’s Jason M. Gerberry noted that Pfizer’s break-up fee is now significantly lower, given the adverse changes in tax law, and the Notice “lowers the probability of the deal closing.”

Related Link: Betting On The Pfizer-Allergan Merger? You Now Have A 35% Arbitrage Opportunity After New Treasury Fears

Key Aspects To Consider

Analyst Jason Gerberry mentioned the key considerations regarding the Treasury update:

  • The Notice proposes a change in the "ownership test," which is used to determine Allergan’s ownership of the new entity formed by the merger, from more than 40 percent to mid-20 percent. This could fall below 20 percent, depending on certain assumptions. This suggests the risk of Pfizer owning more than 80 percent of the new entity and the deal not being considered as an inversion.
  • The Notice includes a provision regarding EPS stripping, “which we don’t see as a deal killer,” Gerberry wrote.
  • Although there are some legal questions regarding the implementation of the Notice, the reduction in breakup fee from $3.5 billion to $400 million could provide Pfizer with “sufficient reason to walk away.”

Recommendations

Leerink maintained a Market Perform rating for Pfizer. Reiterating an Outperform rating for Allergen, Gerberry recommended buying the shares “in any event [whether or not the deal gets completed] if the shares remain at pre-market levels (~$220/shr as of this writing).”

Latest Ratings for PFE

DateFirmActionFromTo
Oct 2017BMO CapitalMaintainsOutperform
Sep 2017Morgan StanleyUpgradesEqual-WeightOverweight
Aug 2017BMO CapitalUpgradesMarket PerformOutperform

View More Analyst Ratings for PFE
View the Latest Analyst Ratings

Posted-In: Jason M. Gerberry LeerinkAnalyst Color Long Ideas Reiteration Analyst Ratings Trading Ideas Best of Benzinga

 

Related Articles (AGN + PFE)

View Comments and Join the Discussion!